Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Cogstate Ltd ( (AU:CGS) ) is now available.
Cogstate Ltd, an ASX-listed cognitive assessment and healthcare technology provider, focuses on delivering digital tools and services to support clinical research and diagnosis in neurology and related therapeutic areas. The company has notified the market that a total of 17,932 performance rights (ASX code: CGSAAI) have lapsed in October 2025 because the conditions attached to these rights were not met or could no longer be satisfied, resulting in a reduction of potential future share issuance but no immediate cash impact, and signalling that certain performance hurdles under its incentive arrangements were not achieved.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is an Australian-listed company on the ASX (code: CGS). The company operates in the cognitive science and healthcare technology sector, providing digital cognitive assessment tools and related services, primarily to pharmaceutical companies, healthcare providers and research institutions involved in neurology and central nervous system disorders.
Average Trading Volume: 317,769
Technical Sentiment Signal: Buy
Current Market Cap: A$425.6M
Learn more about CGS stock on TipRanks’ Stock Analysis page.